Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822208 | 0.96 | CNR1 (0.42) | ADORA1ADORA2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6822494 | 0.88 | ADORA1 (0.43) | ADORA1 | |
| SCHEMBL6818544 | 0.88 | ADORA1 (0.46) | ADORA1KMT2ASMN1; SMN2 | |
| SCHEMBL6822105 | 0.87 | ADORA1 (0.43) | ADORA1ADORA2A | |
| SCHEMBL6822341 | 0.86 | ADORA1 (0.42) | ADORA1 | |
| SCHEMBL6824869 | 0.86 | ADORA1 (0.42) | ADORA1DGAT2 | |
| SCHEMBL6822202 | 0.85 | ALDH1A1 (0.45) | ADORA1MEN1KMT2A | |
| SCHEMBL6821913 | 0.84 | ADORA1 (0.43) | ADORA1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6822354 | 0.84 | ADORA1 (0.43) | ADORA1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6822459 | 0.84 | ADORA1 (0.41) | ADORA1PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885ADORA2A 34/4885MAPK14 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.